Thalidomide and hydroxyurea together for people with beta thalassemia
Tests thalidomide with hydroxyurea for safety and effect in people with beta thalassemia.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia
Key facts
- Where
- Rawalpindi, PakistanSee the site
Where in Pakistan
- Riphah International UniversityRawalpindi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Riphah International University
- Trial code
- NCT07673302
- Record updated
- 6 August 2026
- Original description
The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are:Read full original descriptionShow less
Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia: a Prospective 12 Months Study
The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are:
* To determine the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea) on hemoglobin level and blood transfusion in beta thalassemia patients. * To determine the safety of HbF inducers (combination therapy: thalidomide and hydroxyurea) in beta thalassemia patients * To determine effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on quality of life of beta thalassemia patients
Inclusion: Confirmed diagnosis of Beta thalassemia Major (BTM) ascertained by Hemoglobin Electrophoresis or HPLC report performed pre-transfusion or genetic testing profile (comprising PCR or HBB gene sequencing) suggestive of β-thalassemia syndrome; All ages and both genders will be included; Written informed consent.
Exclusion: History of neurological problems; Pregnancy or unwilling to follow contraception or planning conception (Enrolled female patients will be strictly advised to avoid pregnancy during the study period and until 6 months after thalidomide withdrawal; Hemoglobinopathies other than beta thalassemia; Inability to regularly follow up.